Synedica BPC-157 & TB-500 40mg
Synedica BPC-157 & TB-500 40mg is a research-focused peptide formulation combining BPC-157 and TB-500 in a convenient injection pen kit format. The formulation is positioned within Synedica’s recovery research range and is intended for laboratory, analytical and scientific research rather than human or veterinary use.
Researchers investigating peptide biology can explore BPC-157 and TB-500 in relation to cellular signalling, tissue biology, angiogenesis, cell migration and other biological processes. Current scientific literature remains predominantly preclinical, with limited human evidence, making accurate research-focused presentation particularly important.
Synedica BPC-157 & TB-500 40mg Product Overview
The Synedica BPC-157 & TB-500 40mg formulation contains a combined total of 40mg and is listed by Synedica as a Recovery research formulation in injection-pen format.
| Specification | Product Information |
|---|---|
| Product | Synedica BPC-157 & TB-500 40mg |
| Format | Injection Pen Kit |
| Research compounds | BPC-157 and TB-500 |
| Total formulation amount | 40mg |
| Research area | Recovery / Peptide Research |
| Intended context | Laboratory and scientific research |
For additional information about the Synedica formulation portfolio, visit our Synedica research products collection.
What Is BPC-157?
BPC-157 is a synthetic peptide that has been investigated primarily in preclinical research. Scientific publications have examined its potential effects on processes associated with tissue biology, angiogenesis, inflammatory signalling and musculoskeletal models.
A 2025 systematic review identified a substantial body of preclinical research involving BPC-157, while also highlighting the limited amount of human clinical evidence. Researchers should therefore distinguish experimental findings from established clinical outcomes.
For a detailed scientific overview, researchers can review the peer-reviewed BPC-157 systematic review.
What Is TB-500?
TB-500 is commonly described in peptide research as a synthetic peptide related to Thymosin Beta-4 research. Scientific investigations have examined pathways involving cell migration, cytoskeletal processes, angiogenesis and tissue biology.
Research concerning TB-500 remains considerably more developed in experimental and preclinical settings than in controlled human clinical studies. A recent review of emerging peptides found that human evidence for BPC-157 and TB-500 remains limited and that claims concerning musculoskeletal recovery should not be treated as established clinical outcomes.
BPC-157 & TB-500 Research
The combination of BPC-157 and TB-500 is of interest to researchers studying biological processes associated with tissue repair and cellular responses. BPC-157 research has investigated angiogenesis, inflammatory signalling and musculoskeletal models, while TB-500 research has examined cell migration and cytoskeletal mechanisms.
However, the scientific evidence should be interpreted carefully. A recent peer-reviewed scoping review examining emerging peptides, including BPC-157 and TB-500, found that most of the available literature was based on preclinical models and that robust human clinical evidence remains limited.
Researchers can review the recent peer-reviewed review of peptide research in sports medicine for additional scientific context.
Why Research BPC-157 & TB-500?
- Peptide research: Supports laboratory investigation of two experimentally studied peptides.
- Combined formulation: Contains BPC-157 and TB-500 within one research formulation.
- 40mg specification: Clearly identified total formulation quantity.
- Research-focused format: Designed for controlled scientific and laboratory environments.
- Quality documentation: Product information and verification documentation are available from the manufacturer.
- Recovery research category: Listed within Synedica’s recovery-focused research portfolio.
Synedica BPC-157 & TB-500 40mg Quality Information
Research materials should be evaluated using appropriate analytical and quality documentation. Researchers should review the batch-specific documentation supplied with the product and verify that the relevant identity, purity and quality information corresponds to the material being examined.
Synedica publishes formulation and verification information for its research portfolio. Product documentation should always be reviewed alongside the specific batch supplied.
Explore the Synedica research formulation portfolio for manufacturer-published formulation information.
BPC-157 & TB-500 Research Evidence
Current research should not be confused with established medical treatment evidence. A systematic review of BPC-157 literature published in 2025 identified 36 relevant studies after screening, with 35 being preclinical studies and only one clinical study. The authors concluded that human safety data remain limited.
A 2026 review covering emerging peptide supplements similarly reported that much of the available evidence for BPC-157 and TB-500 comes from preclinical research and that robust human trials remain limited.
This distinction is important when evaluating Synedica BPC-157 & TB-500 40mg: experimental findings can provide useful research hypotheses, but they do not establish that a peptide combination is safe or effective as a human treatment.
Research-Only Information
Synedica BPC-157 & TB-500 40mg is presented as research material and is not intended for human or veterinary consumption. It should not be marketed as a treatment, cure, prevention product or substitute for an approved medical therapy.
BPC-157 and TB-500 remain subjects of ongoing scientific investigation. Researchers should use appropriate institutional procedures, laboratory controls, risk assessments and applicable regulations when handling experimental peptide materials.
Storage & Laboratory Handling
Storage and handling should follow the current manufacturer documentation supplied with the specific product and batch. Researchers should consult the accompanying product documentation for applicable stability and handling information.
Research materials should be handled only within appropriate laboratory procedures. Product information should not be interpreted as individual medical or dosing advice.
Frequently Asked Questions
What is Synedica BPC-157 & TB-500 40mg?
Synedica BPC-157 & TB-500 40mg is a research-focused formulation combining BPC-157 and TB-500 with a stated total amount of 40mg.
What is BPC-157?
BPC-157 is a synthetic peptide investigated primarily in preclinical research involving tissue biology, angiogenesis and related cellular processes.
What is TB-500?
TB-500 is a synthetic peptide associated with research into cellular migration, cytoskeletal processes, angiogenesis and tissue biology.
Is BPC-157 & TB-500 40mg approved as a medicine?
This product is presented as research material rather than an approved medicine. Current scientific evidence for BPC-157 and TB-500 remains predominantly preclinical, with limited human clinical evidence.
What does the 40mg specification mean?
The 40mg specification refers to the total amount stated for the combined research formulation. It should not be interpreted as a recommended human dose.
What research areas involve BPC-157 and TB-500?
Research has investigated areas including tissue biology, cellular signalling, angiogenesis, cell migration and musculoskeletal models. Much of this evidence comes from preclinical research.
Does Synedica provide product documentation?
Synedica publishes formulation and verification information for its research products. Researchers should review the documentation associated with the specific batch they receive.
Where can I explore Synedica research products?
You can browse the Synedica research products collection to explore available formulations and product information.
Explore Synedica BPC-157 & TB-500 40mg
Explore Synedica BPC-157 & TB-500 40mg as a research-focused peptide formulation for laboratory and scientific applications. Review the product information and applicable documentation before purchasing.









Reviews
There are no reviews yet.